CAR T-Cell Therapy for Relapsed/Refractory CLL
2 Bekeken
• 07/14/23
0
0
insluiten
administrator
abonnees
The panelists provide insight on the use of chimeric antigen receptor T-cell therapy for chronic lymphocytic leukemia and the TRANSCEND CLL-004 trial of liso-cel (JCAR017) in relapsed/refractory disease.
Laat meer zien
Facebook Reacties
SORT BY-
Top Reacties
-
Laatste Reacties